91 results on '"Chinnaiyan, Arul M"'
Search Results
2. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
3. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
4. Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance
5. Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
6. Expression of L1 Cell Adhesion Molecule, a Nephronal Principal Cell Marker, in Nephrogenic Adenoma
7. Extragonadal germ cell tumors: A clinicopathologic study with emphasis on molecular features, clinical outcomes and associated secondary malignancies
8. Comprehensive proteogenomic characterization of rare kidney tumors
9. Pan-cancer proteogenomics characterization of tumor immunity
10. Deep learning integrates histopathology and proteogenomics at a pan-cancer level
11. Proteogenomic insights suggest druggable pathways in endometrial carcinoma
12. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation
13. Pan-cancer proteogenomics connects oncogenic drivers to functional states
14. Proteogenomic data and resources for pan-cancer analysis
15. Genomics driven precision oncology in advanced biliary tract cancer improves survival
16. Highly Recurrent IDH1 Mutations in Prostate Cancer With Psammomatous Calcification
17. Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma
18. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma
19. Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes
20. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates
21. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
22. Corrigendum to “Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment” [Neoplasia, Volume 22, Issue 2 (2020) 111–119]
23. Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
24. Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
25. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
26. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays
27. Corrigendum to “Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma” [Neoplasia, Volume 21, Issue 3 (2019) 322–330]
28. Corrigendum to ‘Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment’ Neoplasia, Volume 22, Issue 2 (2020) 111–119
29. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes
30. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer
31. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
32. Long Noncoding RNAs in Cancer: From Function to Translation
33. Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
34. A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer
35. RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin
36. The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc
37. Prostate cancer with Paneth cell–like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification
38. HRAS mutations are frequent in inverted urothelial neoplasms
39. Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing
40. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations
41. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization—a correlative study with urine PCA3 and TMPRSS2-ERG
42. KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
43. The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease
44. Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition
45. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
46. Novel dual-color immunohistochemical methods for detecting ERG–PTEN and ERG–SPINK1 status in prostate carcinoma
47. The Role of Sarcosine Metabolism in Prostate Cancer Progression
48. MetaboID: A graphical user interface package for assignment of 1H NMR spectra of bodyfluids and tissues
49. MicroRNA expression patterns in indeterminate inflammatory bowel disease
50. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.